Bank of America
LXRX icon

Bank of America’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bank of America’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$821K Buy
526,103
+424,006
+415% +$617K ﹤0.01% 4619
2025
Q4 		$117K Buy
102,097
+44,293
+77% +$60.8K ﹤0.01% 5559
2025
Q3 		$78K Buy
57,804
+25,707
+80% +$29.2K ﹤0.01% 6691
2025
Q2 		$30.3K Sell
32,097
-64,290
-67% -$41.7K ﹤0.01% 6953
2025
Q1 		$44.3K Sell
96,387
-40,020
-29% -$25.2K ﹤0.01% 6780
2024
Q4 		$101K Buy
136,407
+29,319
+27% +$35.3K ﹤0.01% 6399
2024
Q3 		$168K Buy
107,088
+19,903
+23% +$35.4K ﹤0.01% 6092
2024
Q2 		$146K Buy
87,185
+1,313
+2% +$2.35K ﹤0.01% 6052
2024
Q1 		$206K Sell
85,872
-124,853
-59% -$268K ﹤0.01% 5874
2023
Q4 		$322K Buy
210,725
+46,249
+28% +$55K ﹤0.01% 5788
2023
Q3 		$179K Buy
164,476
+86,184
+110% +$151K ﹤0.01% 5958
2023
Q2 		$179K Buy
78,292
+17,531
+29% +$46.5K ﹤0.01% 5907
2023
Q1 		$148K Sell
60,761
-1,710
-3% -$3.92K ﹤0.01% 6074
2022
Q4 		$119K Sell
62,471
-47,662
-43% -$101K ﹤0.01% 6166
2022
Q3 		$264K Buy
110,133
+71,823
+187% +$199K ﹤0.01% 5825
2022
Q2 		$71K Sell
38,310
-8,406
-18% -$16K ﹤0.01% 6659
2022
Q1 		$97K Sell
46,716
-229,807
-83% -$637K ﹤0.01% 6881
2021
Q4 		$1.09M Buy
276,523
+257,515
+1,355% +$1.25M ﹤0.01% 5153
2021
Q3 		$91K Sell
19,008
-14,238
-43% -$58.4K ﹤0.01% 6769
2021
Q2 		$153K Sell
33,246
-149,841
-82% -$722K ﹤0.01% 6263
2021
Q1 		$1.07M Buy
183,087
+102,787
+128% +$712K ﹤0.01% 4761
2020
Q4 		$274K Sell
80,300
-95,974
-54% -$183K ﹤0.01% 5393
2020
Q3 		$254K Buy
176,274
+99,211
+129% +$177K ﹤0.01% 5151
2020
Q2 		$154K Buy
77,063
+40,535
+111% +$79.4K ﹤0.01% 5420
2020
Q1 		$71K Sell
36,528
-23,145
-39% -$68.9K ﹤0.01% 5706
2019
Q4 		$248K Sell
59,673
-120,427
-67% -$464K ﹤0.01% 5485
2019
Q3 		$542K Sell
180,100
-99,028
-35% -$307K ﹤0.01% 5034
2019
Q2 		$1.75M Sell
279,128
-91,140
-25% -$546K ﹤0.01% 4135
2019
Q1 		$2.06M Buy
370,268
+337,248
+1,021% +$2.05M ﹤0.01% 3969
2018
Q4 		$220K Sell
33,020
-21,518
-39% -$174K ﹤0.01% 5459
2018
Q3 		$581K Sell
54,538
-33,250
-38% -$381K ﹤0.01% 4849
2018
Q2 		$1.05M Buy
87,788
+4,471
+5% +$45.7K ﹤0.01% 4434
2018
Q1 		$714K Sell
83,317
-89,378
-52% -$827K ﹤0.01% 4602
2017
Q4 		$1.71M Sell
172,695
-448,230
-72% -$4.66M ﹤0.01% 4094
2017
Q3 		$7.63M Buy
620,925
+410,545
+195% +$6.06M ﹤0.01% 2778
2017
Q2 		$3.46M Sell
210,380
-180,639
-46% -$2.8M ﹤0.01% 3392
2017
Q1 		$5.61M Buy
391,019
+139,143
+55% +$2.06M ﹤0.01% 2910
2016
Q4 		$3.48M Buy
251,876
+55,704
+28% +$894K ﹤0.01% 3286
2016
Q3 		$3.55M Sell
196,172
-2,518
-1% -$40.5K ﹤0.01% 3154
2016
Q2 		$2.85M Buy
198,690
+4,349
+2% +$59K ﹤0.01% 3319
2016
Q1 		$2.32M Buy
194,341
+129,299
+199% +$1.36M ﹤0.01% 3440
2015
Q4 		$865K Buy
65,042
+5,537
+9% +$68.1K ﹤0.01% 4459
2015
Q3 		$639K Buy
59,505
+39,705
+201% +$434K ﹤0.01% 4640
2015
Q2 		$159K Buy
19,800
+3,123
+19% +$22.9K ﹤0.01% 5359
2015
Q1 		$111K Buy
16,677
+106
+0.6% +$724 ﹤0.01% 5256
2014
Q4 		$105K Buy
16,571
+1,305
+9% +$10.5K ﹤0.01% 5847
2014
Q3 		$151K Sell
15,266
-24,375
-61% -$260K ﹤0.01% 5658
2014
Q2 		$447K Sell
39,641
-588
-1% -$6.32K ﹤0.01% 4739
2014
Q1 		$487K Sell
40,229
-5,281
-12% -$67.5K ﹤0.01% 4617
2013
Q4 		$573K Sell
45,510
-3,787
-8% -$60.3K ﹤0.01% 4641
2013
Q3 		$821K Buy
49,297
+3,351
+7% +$56.2K ﹤0.01% 4148
2013
Q2 		$697K Buy
+45,946
New +$698K ﹤0.01% 4413

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America's LXRX Position: Q1 2026 in Review

Bank of America increased its Lexicon Pharmaceuticals (LXRX) stake by 415% in Q1 2026, buying an estimated $617K and bringing the position to 526,103 shares worth $821K. The position accounts for ﹤0.01% of the portfolio, ranked #4619.

Bank of America first reported a position in LXRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.63M in Q3 2017. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Bank of America held 526,103 shares of Lexicon Pharmaceuticals worth $821K as of Q1 2026.
  • Bank of America bought 424,006 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $617K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4619 holding.
  • Bank of America first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Lexicon Pharmaceuticals position peaked at $7.63M in Q3 2017.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.